Lifecare ASA Annual Report 2024
Bergen, Norway, 28 March – Lifecare ASA (LIFE), a medical sensor company advancing product development for the next-generation Continuous Glucose Monitoring (CGM), has today published its 2024 Annual Report.
Lifecare ASA has today released its 2024 Annual Report, providing insights into Lifecare’s business strategy, key milestones, and next steps toward obtaining CE certification for its glucose sensor for use in the human market.
2024 has been a transformative year for Lifecare, marked by significant advancements in technology, strategic development, and market readiness. The company has made substantial progress in developing its glucose sensor, scaling up for large-scale manufacturing, strengthening its organization, and moving closer to commercialization.
Lifecare is entering a pivotal phase in 2025, maintaining strong momentum in product development and preparing for commercialization. Lifecare’s continuous glucose monitoring technology continues to advance, supported by strategic partnerships, optimized production processes, and improvements in sensor sensitivity. Lifecare anticipates finalizing the design of the Sencell implant in the first half of 2025, ensuring it is optimized for manufacturing. At the same time, Lifecare is preparing for the regulatory study to support the CE mark application for Sencell in the human market. This study is expected to start late 2025, with the main part taking place in 2026, targeting CE approval and market launch by 2027.
The Annual Report is published in both the European Single Electronic Format (ESEF) and as an PDF.
Additionally, Lifecare has published its 2024 Remuneration Report in accordance with the Norwegian Public Limited Liability Companies Act, section 6-16b (2).
The reports are available on Lifecare’s website: https://lifecare.no/investor/reports-presentations/.